Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
First-in-class drug targets ‘undruggable’ MYC in blood cancers
9+ hour, 15+ min ago (611+ words) Researchers at MD Anderson Cancer Center have identified a previously unknown feedforward relationship between MYC and GSPT1, and developed a dual-degrader strategy that showed potent preclinical activity across a variety of blood cancers. A first-in-class therapy targeting MYC, a protein long…...
How AI-driven systems biology will reset the starting line for drug development
11+ hour, 57+ min ago (340+ words) AI is accelerating drug discovery, yet attrition rates remain high. Its greatest impact may lie not in finding drugs faster, but in helping researchers understand the complex biology driving disease. If AI is making drug discovery dramatically faster, why isn’t…...
600+ patient-derived cancer models expand the search for drug targets
3+ day, 10+ hour ago (923+ words) Developed through the Human Cancer Models Initiative (HCMI), the collection represents 25 cancer types, with most models generated as three-dimensional organoids from patient tumour samples. The international programme was launched to increase the number and diversity of models available for cancer…...
IL-17 biomarker may predict immunotherapy response in clear cell ovarian cancer subtype
3+ day, 10+ hour ago (584+ words) New research has identifies elevated IL-17 activity in approximately 5 percent of clear cell ovarian cancer cases, with findings suggesting the inflammatory protein may convert immunologically ‘cold’ tumours into environments receptive to immune checkpoint inhibition. Researchers have identified a small subtype of…...
Exhausted T cells escape tumours to drive lasting cancer immunity
4+ day, 11+ hour ago (478+ words) Researchers at the University of Pittsburgh have discovered that a population of exhausted intratumoral T cells expressing the inhibitory receptor LAG3 can lose that marker, exit the tumour microenvironment and seed durable peripheral immunity. Scientists at the University of Pittsburgh have…...
Why researchers are revisiting bisantrene decades after it was abandoned
4+ day, 11+ hour ago (1357+ words) This cookie helps protect the website and its users against Cross-Site Request Forgery (CSRF) attacks. It ensures that form submissions and other authenticated requests are made intentionally by the user and not by malicious scripts from other sites. This cookie…...
NUS researchers identify molecular switch driving TNBC treatment resistance
5+ day, 7+ hour ago (451+ words) A new study has identified DP103 as a key regulator of Wnt signalling, cancer stemness and treatment resistance in triple-negative breast cancer, and proposes the protein as a diagnostic biomarker to guide precision use of the investigational drug RX-5902. Researchers at…...
First multi-responsive foldamer-based gel offers new approach to controlled drug delivery
5+ day, 10+ hour ago (680+ words) A team at the University of Birmingham has developed the first multi-responsive gel constructed from foldamers – synthetic molecules that fold into defined shapes – capable of switching between gel and liquid-like states in response to UV light, heat and acid. Scientists…...
Targeting childhood myopia progression with 7-methylxanthine
5+ day, 14+ hour ago (780+ words) Dr Klaus TrierAugust 19, 2026 Childhood myopia researcher Dr Klaus Trier explores how 7-methylxanthine targets scleral remodelling and axial elongation, and its potential to slow disease progression and reduce the risk of high myopia. Childhood myopia (short-sightedness) has become one of the…...
Patient-specific brain tumour chip models vascular drug barriers
6+ day, 6+ hour ago (50+ words) Drug Target Review Patient-specific brain tumour chip models vascular drug barriers Researchers at KAIST and collaborating institutions have developed a patient-specific blood–brain tumour barrier chip that replicates the vascular environment surrounding glioblastoma tumours. Only registered users can comment on…...